Oculis Holding AG (OCS) Convertible Debt (2023 - 2024)

Oculis Holding AG's (OCS) quarterly Convertible Debt came in at $433067.9 in Q1 2024, up 1.63% quarter-over-quarter from $426140.0 in Q4 2023.

Oculis Holding AG (OCS) Convertible Debt (2023 - 2024) Analysis & Trends

Oculis Holding AG's Convertible Debt history runs 2 years deep, the most recent figure standing at $433067.9 for Q1 2024.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $433067.9 in Q1 2024; TTM through Mar 2024 was $433067.9, a N/A change from a year earlier, with the FY2023 full-year figure at $420881.6, changed N/A from the prior year.
Convertible Debt rose to $433067.9 in Q1 2024 per OCS's latest filing, from $426140.0 in the prior quarter.
Across five years, Convertible Debt topped out at $433067.9 in Q1 2024 and bottomed at $426140.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alnylam Pharmaceuticals	35.71 Bn	32.70 Bn	959.66 Mn

Download Data